Engflag

Spasmex 15

Quick links to important sections

Spasmex 15

Spasmex 15_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Spasmex 15

Quick Facts: Spasmex 15 (Trospium Chloride)

Property Description
Active ingredient Trospium Chloride
Form Immediate-release tablet
Pharmacological class Anticholinergic agent / Muscarinic antagonist
General purpose Management of excessive bladder contractions
Origin Synthetic compound

What Type of Medication is Spasmex 15?

Spasmex 15 is a synthetic, prescription-only medication officially classified as an anticholinergic agent and a muscarinic antagonist. Its active substance is Trospium Chloride, which falls under the established pharmacological class of Cholinergic Muscarinic Antagonists. This compound is recognized in pharmacological studies for its unique structure as a quaternary ammonium compound, a feature that limits its ability to cross the blood-brain barrier and supports its targeted action outside the central nervous system. This specific chemical nature is often a differentiating factor compared to older agents in the same class.

Composition and Form: Trospium Chloride and Its Presentation

The medication is an immediate-release tablet formulated for oral administration, containing 15 milligrams of the active ingredient, Trospium Chloride. Spasmex 15 is a single-ingredient product and is presented as an oral tablet. The immediate-release format is designed to facilitate prompt absorption of Trospium Chloride into the bloodstream, which is a key characteristic that distinguishes it from formulations designed for a slower delivery over time.

General Purpose: Managing Excessive Bladder Activity

The general therapeutic purpose of Spasmex 15 is to relieve symptoms caused by the excessive or involuntary contractions of the urinary bladder muscles. The drug is clinically recognized for its antispasmodic effects on the bladder wall, which is typically used for adult patient groups experiencing overactive bladder symptoms. As a urinary antispasmodic, its primary function is to interrupt the signaling pathway involving the chemical messenger acetylcholine, thereby helping to stabilize the bladder and improve its ability to store urine.

Regulatory References

  1. Trospium Chloride Label (NIH/DailyMed)
  2. Trospium: MedlinePlus Drug Information

What side effects are possible with Spasmex 15?

Spasmex 15 (trospium chloride) is a medication used to treat overactive bladder. As with any medication, side effects can occur, although not everyone experiences them. Side effects are typically related to the drug's anticholinergic properties.

Potential Side Effects

Very Common and Common Side Effects

The most frequently reported side effects include dry mouth, constipation, and headache. Other common gastrointestinal effects include dyspepsia (indigestion), nausea, and abdominal pain. Some individuals may also experience blurred vision or dry eyes.

Less Common and Serious Side Effects

Less common side effects can include dizziness, drowsiness, flatulence, and tachycardia (fast heart rate). Serious, though rare, side effects may involve:

  • Allergic Reactions (Angioedema): Swelling of the face, lips, tongue, or throat, which can be life-threatening and requires immediate medical attention.
  • Urinary Retention: Difficulty or inability to empty the bladder.
  • CNS Effects: Confusion, hallucinations, or somnolence, particularly in older patients.

Safety Information and Contraindications

Spasmex 15 is contraindicated in patients with certain pre-existing conditions due to increased risk of adverse effects. Do not take this medication if you have:

  • Urinary retention
  • Uncontrolled narrow-angle glaucoma
  • Tachyarrhythmia
  • Myasthenia gravis
  • Severe chronic inflammatory bowel disease (Crohn's disease, ulcerative colitis, or toxic megacolon)

Caution is advised in patients with kidney or liver impairment, as dosage adjustments may be necessary. Because this medication may cause blurred vision or dizziness, patients should not drive or operate heavy machinery until they know how they react to the drug. Alcohol consumption is not recommended as it may intensify drowsiness.

Special consideration is needed for older patients, as they may be more susceptible to anticholinergic side effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the Trospium Chloride overdose profile as the manifestation of exaggerated anticholinergic effects. Documented overdose presentations include cardiovascular signs such as tachycardia (fast heartbeat), ocular effects like widened pupils, and Central Nervous System (CNS) symptoms including confusion, hallucinations, and somnolence (drowsiness). Gastrointestinal and urinary signs, such as dryness of the mouth and disorders of micturition, are also listed.

The official labeling mandates that individuals call emergency services or a Poison Control center immediately if an overdose is suspected. Urgent medical help is specifically required for severe, life-threatening outcomes, including collapse, trouble breathing, or any indication of angioedema (swelling of the face, tongue, or larynx) which may compromise the airway. If upper airway swelling occurs, the medication must be promptly discontinued and immediate measures taken to ensure a patent airway.

Management is described as symptomatic and supportive. Regulator-documented procedures include gastric lavage and the use of activated charcoal to reduce absorption. For severe symptoms, the use of a parasympathomimetic agent may be indicated. ECG monitoring is officially recommended in the event of overdosage. Furthermore, the risk of severe anticholinergic adverse reactions is expected to be greater in patients with moderate or severe renal impairment.

Therapeutic Uses of Spasmex 15

Quick Facts

  • Targeted Conditions: Overactive bladder (OAB), neurogenic detrusor overactivity, vegetative bladder dysfunction.
  • Key Symptom Relief: Helps manage urinary urgency, increased frequency of urination, and urge urinary incontinence.

What Spasmex 15 Treats: Main Uses and Benefits

Spasmex 15 (trospium chloride) is a prescription treatment designated for managing symptoms associated with an overactive bladder (OAB). The active component is part of a class of agents that help promote relaxation of the smooth muscles in the urinary bladder.

The therapy is used to address the main manifestations of OAB, which include a sudden, difficult-to-defer feeling of the need to urinate, known as urinary urgency. It assists in reducing the number of daily micturition episodes (frequency) and may contribute to a reduction in the occurrence of urge urinary incontinence (involuntary loss of urine). The medication may also be utilized to support the management of impaired bladder function or neurogenic detrusor overactivity, which is an overactivity of the bladder muscle that can be related to a neurological condition.

Individuals seeking treatment options for these conditions may consult their healthcare professional to assess the relevance of this therapy.

Eligibility and Restrictions for Use

Spasmex 15 (trospium chloride) is a prescription medicine, and eligibility for its use is strictly determined by a patient's clinical state and age, as defined in regulatory labeling.

Contraindications (Must NOT Use)

The medicine is contraindicated (absolutely prohibited) for patients with a known hypersensitivity to the drug or its ingredients. It must not be used in those who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, tachyarrhythmia (increased and irregular heartbeat), or toxic megacolon.

Special Restrictions and Considerations

Age and Pediatric Use: Spasmex 15 is generally intended for adults and adolescents aged 12 years and older. Its use is not recommended in children under 12, as safety and efficacy data are not established for this younger population.

Organ Impairment: Treatment is not recommended for patients with severe hepatic impairment (severe liver dysfunction) due to lack of clinical data. For patients with severe renal impairment (CCr 10-30 mL/min/1.73 m^2), the dose must be restricted to a lower maximum daily intake. Use is fully contraindicated for patients with renal disease requiring dialysis (CCr < 10 mL/min/1.73 m^2).

Pregnancy and Lactation: Use during pregnancy and breast-feeding is not recommended unless a physician determines the potential benefits outweigh the lack of human experience and potential risk. It should only be used after a close examination of the indication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Spasmex 15 (trospium chloride) is defined by pharmacokinetic and pharmacodynamic constraints, as documented in regulatory labeling.

Pharmacokinetic Interactions and Administration Constraints

Co-administration with a high-fat meal results in a significant reduction—approximately 70% to 80%—in trospium's systemic exposure (AUC and Cmax). Due to this clinically significant interaction, the immediate-release tablet form must be taken on an empty stomach, at least one hour before a meal.

Trospium is largely eliminated through active renal tubular secretion. Concomitant use with other medicinal products that are also eliminated through this pathway creates the potential for competition for clearance. For example, co-administration with Metformin Immediate-Release has been documented to reduce the systemic exposure of trospium.

In vitro studies reviewed by regulators indicate that trospium chloride is not expected to contribute significantly to cytochrome P450 (CYP) enzyme interactions, as it shows a lack of inhibition toward major CYP isoenzymes.

Pharmacodynamic Interactions

Co-administration with other anticholinergic agents (antimuscarinic drugs) increases the risk or severity of anticholinergic effects due to pharmacodynamic additivity. Similarly, combining Spasmex 15 with medicines that decrease gastrointestinal motility may potentiate the risk of gastric retention.

Population-Specific Notes

In patients with moderate renal impairment, systemic exposure to trospium is expected to be increased, which is formally noted as leading to a greater risk of experiencing anticholinergic adverse reactions.

Mechanism of Action

Spasmex 15 acts primarily as a non-selective muscarinic receptor antagonist. It exhibits a high affinity for muscarinic cholinergic receptors, particularly the M1, M2, and M3 subtypes. The drug operates by competitive antagonism, binding reversibly to these receptors, thereby preventing the binding of the neurotransmitter acetylcholine (ACh) and inhibiting its subsequent signaling cascade. This inhibitory interaction principally occurs in the smooth muscle of the detrusor muscle within the bladder wall.

This molecular blockade limits the influx of calcium ions ( Ca^2+) into the smooth muscle cell cytoplasm. Reduced intracellular Ca^2+ concentrations impair the activation pathway of myosin light chain kinase (MLCK). Consequently, the drug dampens the spontaneous and evoked depolarization of the detrusor smooth muscle fibers, decreasing the frequency of action potentials and resulting in a decrease in the overall intrinsic contractility of the bladder musculature.

Dosage and Administration Information

Spasmex 15 (trospium chloride) is administered orally as an immediate-release tablet. The primary method of administration is governed by defined dosing schedules and conditions related to intake timing.

Administration Scope

Feature Official Instruction
Route of administration Oral administration only.
Dosing schedule The total daily dose is typically 45 mg (e.g., 15 mg three times daily) in common regimens, or 40 mg (e.g., 20 mg twice daily) in alternative regimens.
Timing in relation to meals Must be taken at least one hour before a meal on an empty stomach to ensure proper drug absorption.
Preparation requirements The tablet must be swallowed whole with sufficient water.
Age-group administration rules Use is not recommended for children under 12 years of age. For geriatric patients, a dose adjustment to 20 mg once daily may be used based on tolerability.
Special procedural conditions In cases of severe renal impairment (kidney dysfunction), the maximum daily dose must be reduced to a specific limit, such as 15 mg total per day.

Instruction Classifications

Classification Official Pattern
Administration method type Oral
Frequency pattern Divided daily use (e.g., Twice daily or Three times daily).
Use-context constraints Time-dependent (prior to food) and Population-dependent (renal impairment).

Resulting Procedural Structure

Official step sequence:

  • Take the prescribed dose of the immediate-release tablet.
  • Ensure intake occurs on an empty stomach and at least one hour before a meal.
  • Maintain the prescribed divided dose frequency (twice or three times daily).
  • Adhere to the reduced maximum dose if severe renal impairment is present.
  • Undergo periodic clinical re-evaluation (e.g., every three to six months) to assess the need for continued use.

The oral administration protocol is defined by a specific dosing amount, a fixed frequency, and the critical requirement of intake on an empty stomach. These instructions govern the proper conditions of use, including mandatory dose adjustments for patients with reduced kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Area of Investigation

Research has explored whether the drug, in the area of serotonin regulation, may be associated with changes in the experience of individuals diagnosed with treatment-resistant depression (TRD). Studies examined whether the drug may be associated with changes when used as an add-on treatment in persons who had not shown an adequate response to their current antidepressant.

Key Clinical Trial Findings

Study Results and Rating Scales

Several randomized controlled trials (RCTs) have been conducted to evaluate the drug's investigational use. One study reported findings that suggested an observed differences in scores on depression rating scales over a 12-week period. Research examined the use of this option in individuals who had not responded to other selective serotonin reuptake inhibitors (SSRIs). The focus of the primary analysis was differences in scores on standardized depression rating scales.

Combined Use Studies

Research evaluated whether the investigational combined use of this drug with an SSRI might be associated with a different frequency of relapse compared to monotherapy. Studies describing the use of this drug often involved individuals continuing their existing antidepressant medication during the trial period. The results varied across different populations and study designs.

Specialized Populations and Functional Measures

Data also suggested an observed association between the drug and changes in cognitive function in a subset of study participants. Measures related to functional status, such as the ability to participate in social and work activities, were also evaluated in clinical research.

Research has also explored the drug's activity in conditions such as bipolar depression, although evidence remains limited. Further clinical research is being conducted to explore the potential role of the drug in anxiety disorders and generalized depressive symptoms outside the scope of TRD.

Reported Events in Trials

The most commonly reported occurrences of events in studies included nausea, dizziness, and sedation. Researchers examined the incidence of these events over the short-term. The reported rate of study discontinuation associated with long-term use was examined. Studies noted that the reported occurrences of adverse events may differ when the drug is used as a standalone treatment versus in combination with other agents.

Key Studies & References

  1. Vilazodone for Major Depressive Disorder: A Review of Efficacy, Safety, and Tolerability (Pooled Analysis of Phase III Trials)

Frequently Asked Questions (FAQ)

Common questions about Spasmex 15 (FAQ)

Q: How long does it typically take to feel the effects of Spasmex 15?

According to official product information, the active ingredient reaches its peak concentration in the bloodstream, or Cmax, approximately 5 to 6 hours after taking the immediate-release tablet. This pharmacokinetic information relates to when the drug is maximally present in the system.

Q: Will Spasmex 15 work for me right away or does it take a few weeks?

Clinical trials often assess the full clinical benefit of the medication in improving overactive bladder symptoms over a period of 12 weeks of continuous, regular use. While the active component is absorbed quickly, the clinical benefit observed in studies is generally assessed over a period of several weeks.

Q: How long does the effect of one Spasmex 15 tablet last?

Official regulatory documents indicate that the elimination half-life of the active ingredient is approximately 20 hours following oral intake. The half-life refers to the time it takes for the body to reduce the concentration of the drug by half.

Q: What is the expected timeline for Spasmex 15 to reduce frequency?

Official studies designed to demonstrate the efficacy of this medicine typically report their results on frequency and other symptoms after a full course of treatment, such as a 12-week period. This timeline is used in research to assess the medication’s potential effects.

Q: Is Spasmex 15 a medication that needs to be taken long-term?

Official documentation notes that the need for continued treatment is typically assessed through periodic clinical re-evaluation. Healthcare providers often re-evaluate the ongoing necessity of the medication, usually every three to six months.

Q: Are the reported side effects the same for all doses of Spasmex 15?

Regulatory information indicates that dosage adjustments, such as a reduction in the daily amount, are often recommended for certain populations, including older patients and those with severe kidney impairment. This adjustment is done specifically to manage or limit the potential for anticholinergic side effects.

Q: Can Spasmex 15 cause or worsen symptoms of Gastroesophageal Reflux Disease (GERD)?

The medication's effect on the body can potentially decrease gastrointestinal motility (the movement of food through the gut). For this reason, official safety information notes caution is advised and lists specific, severe gastrointestinal conditions as a contraindication.

Q: Can Spasmex 15 be used for bladder spasms that are not related to OAB?

The regulatory indication for this medicine is specifically limited to the treatment of the symptoms associated with Overactive Bladder (OAB), which includes urgency, frequency, and urge incontinence.

Q: Is Spasmex 15 ever prescribed to children?

Official regulatory documents state that the safety and effectiveness of the tablet formulation have not been established in pediatric patients. Therefore, the medication is not recommended for children under 12 years of age.

Q: Is it safe to take Spasmex 15 with cold and flu medicine?

Official product information states that caution is noted when the medicine is used with other medications that also possess anticholinergic effects. Since many cold and flu medicines contain anticholinergic properties, combining them may increase the risk and severity of side effects like dry mouth or constipation.

Q: Can certain supplements or vitamins affect Spasmex 15?

Official regulatory sources indicate that the absorption of the active ingredient may be inhibited when taken alongside certain substances, such as guar, cholestyramine, and colestipol. Simultaneous use with these substances is not recommended.

Q: What are the most common reasons patients stop taking Spasmex 15?

The most frequently reported events in clinical trials that led to patients discontinuing treatment were the common anticholinergic side effects. These included dry mouth, constipation, abdominal pain, and urinary retention.

Q: What is the risk of taking Spasmex 15 for older adults?

Official prescribing information notes that older adults aged 75 and over showed a higher incidence of commonly reported anticholinergic adverse reactions. This indicates that this patient population may have an enhanced sensitivity to the medication's side effects.

Q: If the medication doesn't seem to be working after a week, is that normal?

Clinical studies generally assess the full efficacy of the medication over a timeframe of 12 weeks. Therefore, the initial effects observed after only one week of use may not represent the final therapeutic outcome.

Q: Why do some people experience hallucinations with Spasmex 15?

The medication is associated with anticholinergic Central Nervous System (CNS) effects. Official adverse event reporting has included rare cases of confusion, dizziness, somnolence, and hallucinations as potential CNS effects.

Q: Can Spasmex 15 be taken at the same time as other anticholinergic drugs?

Official drug interaction information warns that taking Spasmex 15 alongside other anticholinergic agents (antimuscarinic drugs) is associated with an increased risk and severity of anticholinergic side effects due to additive effects.

Q: How does Spasmex 15 compare to other anticholinergic medications for bladder control?

The active ingredient, Trospium Chloride, is specifically described in regulatory documents as a quaternary ammonium compound. This unique chemical structure is a factor noted for limiting its ability to cross the blood-brain barrier.

Q: Is it true that Spasmex 15 has limited effects on the Central Nervous System (CNS)?

Official documentation notes that the active ingredient, Trospium Chloride, is a quaternary ammonium compound. This chemical characteristic is described as limiting its ability to penetrate the Central Nervous System (CNS).

Q: Is there evidence to suggest Spasmex 15 is less likely to cause cognitive impairment in older adults?

Official labeling advises that the medicine is associated with CNS effects, which can include confusion and somnolence. Patients, particularly older adults, should be monitored for signs of cognitive changes while using the drug.

Q: What is the interaction between Metformin and Spasmex 15?

Official drug interaction studies indicate that taking Spasmex 15 with immediate-release Metformin can reduce the systemic exposure of Trospium Chloride. This occurs because the drugs may compete for elimination through the kidneys.

Q: Does Spasmex 15 treat OAB symptoms or the cause of the problem?

The regulatory indication for this medicine is clearly for the treatment of symptoms associated with overactive bladder, such as frequent urination and sudden urges. It is not designated to resolve the underlying cause of the condition.

Q: What do the clinical studies say about the effectiveness of Spasmex 15?

Clinical trials examining the drug in patients with OAB reported significant changes in key symptoms, including a reduction in the daily number of voids and the frequency of urge urinary incontinence episodes when compared to the start of the study.

Q: Has Spasmex 15 been studied against placebo for OAB symptoms?

Yes, regulatory documentation and supporting research show that multiple randomized, controlled trials were conducted. These studies specifically compared the drug’s efficacy to a placebo (an inactive substance) in subjects with overactive bladder.

Q: How does the drug's hydrophilic structure affect its use?

The active ingredient is chemically described as a quaternary ammonium compound, a hydrophilic structure (water-loving). This characteristic is noted in regulatory documents as limiting its ability to pass across lipid membranes, such as the blood-brain barrier.

How should Spasmex 15 be stored and disposed of?

Storage and Disposal Requirements

Item Regulatory Requirement
Storage Temperature The product does not require any special storage conditions in terms of temperature for the unopened package.
Protection Conditions Tablets must be stored in the original blister pack or container to protect the contents from light and moisture until the expiration date.
Child Safety The medication must be kept out of the sight and reach of children to prevent accidental exposure.
Disposal of Unused Product Unused or expired tablets must not be disposed of via household waste or wastewater (do not flush or place in regular trash).
Disposal Instructions Disposal must follow local regulatory requirements; often, this means returning the product to a pharmacist or an authorized collection point.

These official statements define that the product's stability is maintained by storing it in its original packaging and ensuring protection from light and moisture, often with no special temperature limits applied. Safe disposal is mandated by regulatory bodies to prevent environmental contamination, requiring that the medicine be handled as regulated pharmaceutical waste and not discarded in the sink or trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Spasmex 15 found in:

A-Z Index: